Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group
Journal of Clinical Medicine · 19.03.2026 · 15 (6) · 2353
DOI: 10.3390/jcm15062353 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 19.03.2026. Verfasst von Sedat Yıldız und 40 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Vandetanib and cabozantinib are the approved first-line antiangiogenic multikinase inhibitors (aaMKIs) for metastatic medullary thyroid carcinoma (MTC); however, real-world data on their comparative efficacy, optimal sequencing, and outcomes beyond the first-line setting remain limited. We report multicenter real-world outcomes from a large Turkish cohort.
Methods
In this retrospective multicenter cohort study, we analyzed data from 24 oncology referral centers across Türkiye. Patients with histologically confirmed metastatic MTC who received systemic therapy between December 2011 and December 2024 were included. The primary endpoint was progression-free survival (PFS), assessed separately for first-line (PFS1) and second-line (PFS2) therapy. Overall survival (OS) and prognostic factors were evaluated using Kaplan–Meier and Cox proportional hazards analyses.
Results
A total of 115 patients were included (median age 47.4 years; 63.5% male). In the first-line setting, vandetanib (47.8%) and cabozantinib (30.4%) were the most frequently used agents. Median PFS1 was 40.8 months with vandetanib and was not reached with cabozantinib; both were significantly superior to chemotherapy (median PFS1 4.9 months; log-rank p < 0.001). In the second-line setting, median PFS2 was not reached with cabozantinib and was 32.5 months with vandetanib. Sequential use of cabozantinib and vandetanib across the first two lines was associated with a median time to second progression of 114 months, compared with 39 months in patients receiving any other TKI combination (p = 0.003). Second-line use of cabozantinib or vandetanib was independently associated with improved OS (HR 0.40, 95% CI 0.16–0.98; p = 0.046). On multivariate analysis, younger age (HR 0.16, 95% CI 0.03–0.72; p = 0.017) and bone metastasis (HR 0.29, 95% CI 0.11–0.73; p = 0.009) were independent prognostic factors for OS.
Conclusions
In this real-world cohort of patients with metastatic MTC, cabozantinib and vandetanib demonstrated durable efficacy across treatment lines, substantially outperforming alternative TKIs and chemotherapy. Sequential use of both approved aaMKIs was associated with prolonged disease control. These findings suggest a potential association between access to both agents and improved outcomes. They are consistent with their central role in treatment sequencing, particularly in settings with limited access to selective RET inhibitors. Given the retrospective design and small subgroup sizes, these results should be interpreted as exploratory and hypothesis-generating.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey.
- Department of Medical Oncology, Faculty of Medicine, Ege University, İzmir 35100, Turkey.
- Department of Medical Oncology, Faculty of Medicine, Dicle University, Diyarbakır 21280, Turkey.
- Department of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University, Istanbul 34452, Turkey.
- Department of Medical Oncology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul 34147, Turkey.
- Department of Medical Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon 61080, Turkey.
ORCID-Profile: Sedat Yıldız, Talha Özüdoğru, Damla Günenç, Zeynep Sıla Gökdere, Hayati Arvas, Seda Jeral Evinç, Özkan Alan, Rumeysa Çolak, Mesut Yılmaz, Esra Aşık, Atila Yıldırım, Ali Kaan Güren, Osman Köstek, Berkan Karabuğa, Öztürk Ateş, Tuğba Yavuzşen, Şuheda Ataş İpek, Havva Yeşil Çınkır, Elif Şahin, Seray Saray, Selahattin Çelik, Hayriye Şahinli, Didem Divriklioğlu
Zitieren
APA
Yıldız, S., Demir, H., Özüdoğru, T., Günenç, D., Gökdere, Z. S., Arvas, H., Urakçı, Z., Jeral Evinç, S., Alan, Ö., Çolak, R., Yılmaz, M., Aşık, E., Yıldırım, A., Güren, A. K., Köstek, O., Karabuğa, B., Ateş, Ö., Şencan, C., Yavuzşen, T., …, & Kılıçkap, S. (2026). Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group. Journal of Clinical Medicine, 15(6), 2353. https://doi.org/10.3390/jcm15062353
Vancouver
Yıldız S, Demir H, Özüdoğru T, Günenç D, Gökdere ZS, Arvas H, et al. Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group. Journal of Clinical Medicine. 2026;15(6):2353. doi:10.3390/jcm15062353
BibTeX
@article{Yldz2026,
author = {Yıldız, Sedat and Demir, Hacer and Özüdoğru, Talha and Günenç, Damla and Gökdere, Zeynep Sıla and Arvas, Hayati and Urakçı, Zuhat and Jeral Evinç, Seda and Alan, Özkan and Çolak, Rumeysa and Yılmaz, Mesut and Aşık, Esra and Yıldırım, Atila and Güren, Ali Kaan and Köstek, Osman and Karabuğa, Berkan and Ateş, Öztürk and Şencan, Canberk and Yavuzşen, Tuğba and İpek, Şuheda Ataş and Kara, İsmail Oğuz and Şakalar, Teoman and Gökay, Ahmet Cebeli and Yeşil Çınkır, Havva and Dişli, Ahmet Kürşad and İnanç, Mevlüde and Ünal, Olçun Ümit and Yılmaz, Emre and Hacıbekiroğlu, İlhan and Kitaplı, Sait and Tanrıverdi, Özgür and Şahin, Elif and Sağıroğlu, Muhammed Fatih and Yumuştutan, Pembegül and Saray, Seray and Çelik, Selahattin and Şahinli, Hayriye and Gökmen, Azer and Kahveci, Gizem Bakır and Divriklioğlu, Didem and Kılıçkap, Saadettin},
title = {Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {6},
pages = {2353},
doi = {10.3390/jcm15062353}
}
EUVIMED